Dermata Therapeutics, Inc. SEC filings DRMA
Dermata Therapeutics, Inc. has 371 filings in SEC EDGAR's recent list, going back to Apr 2, 2021. Its latest annual report, Form ARS, was filed on Apr 17, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 29, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| SCHEDULE 13G | Ownership over 5% (passive) | Nov 2, 2026 | — |
| 8-K |
Current report
Other events
|
Oct 29, 2026 | Oct 29, 2026 |
| 424B3 | Prospectus | Oct 21, 2026 | — |
| EFFECT | Filing | Oct 20, 2026 | — |
| S-3 | Shelf registration | Oct 9, 2026 | — |
| 4 | Insider transaction | Aug 18, 2026 | Aug 16, 2025 |
| 4 | Insider transaction | Aug 18, 2026 | Aug 16, 2026 |
| 25-NSE | Delisting notice | Aug 17, 2026 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Aug 17, 2026 | Aug 16, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Other events
|
Aug 5, 2026 | Aug 5, 2026 |
| 4 | Insider transaction | Jun 16, 2026 | Jun 16, 2026 |
| S-8 | Employee stock plan registration | Jun 4, 2026 | — |
| SCHEDULE 13D | Ownership over 5% (active) | Jun 1, 2026 | — |
| EFFECT | Filing | May 29, 2026 | — |
| 424B3 | Prospectus | May 29, 2026 | — |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
May 27, 2026 | May 27, 2026 |
| CORRESP | Letter to the SEC | May 27, 2026 | — |
| S-3/A | Filing | May 22, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 13, 2026 | — |
| 10-Q | Quarterly report | May 13, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 13, 2026 | Mar 31, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Apr 22, 2026 | — |
| ARS | Annual report to shareholders | Apr 17, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Apr 17, 2026 | — |
| DEF 14A | Proxy statement | Apr 17, 2026 | Apr 17, 2026 |
| PRE 14A | Preliminary proxy statement | Apr 7, 2026 | Apr 6, 2026 |
| 10-K | Annual report | Mar 26, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 26, 2026 | Mar 26, 2026 |
| 4 | Insider transaction | Mar 17, 2026 | Feb 17, 2026 |
| 8-K |
Current report
Officer or director change
|
Feb 25, 2026 | Feb 23, 2026 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Feb 23, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 18, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 17, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 9, 2026 | — |
| 8-K |
Current report
Auditor change
|
Feb 3, 2026 | Jan 30, 2026 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Feb 2, 2026 | — |
| EFFECT | Filing | Jan 29, 2026 | — |
| 424B3 | Prospectus | Jan 29, 2026 | — |
| CORRESP | Letter to the SEC | Jan 27, 2026 | — |
| UPLOAD | Letter from the SEC | Jan 27, 2026 | — |
| 8-K |
Current report
Other events
|
Jan 27, 2026 | Jan 27, 2026 |
| 424B5 | Prospectus supplement | Jan 27, 2026 | — |
| S-3 | Shelf registration | Jan 22, 2026 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Jan 8, 2026 | — |
| D | Filing | Jan 7, 2026 | — |
| 4 | Insider transaction | Jan 6, 2026 | Jan 2, 2026 |
| 4 | Insider transaction | Jan 6, 2026 | Jan 2, 2026 |
| 4 | Insider transaction | Jan 6, 2026 | Jan 2, 2026 |
| 4 | Insider transaction | Jan 6, 2026 | Jan 2, 2026 |
| 4 | Insider transaction | Jan 6, 2026 | Jan 2, 2026 |
| 4 | Insider transaction | Jan 6, 2026 | Jan 2, 2026 |
| 4 | Insider transaction | Jan 6, 2026 | Jan 2, 2026 |
| 4 | Insider transaction | Jan 6, 2026 | Jan 2, 2026 |
| 4 | Insider transaction | Jan 6, 2026 | Jan 2, 2026 |
| 4 | Insider transaction | Jan 6, 2026 | Jan 2, 2026 |
| 4 | Insider transaction | Jan 6, 2026 | Jan 2, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Jan 2, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Dec 30, 2025 | — |
| 4 | Insider transaction | Dec 29, 2025 | Dec 23, 2025 |
| 4 | Insider transaction | Dec 29, 2025 | Dec 23, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Dec 29, 2025 | Dec 23, 2025 |
| S-3 | Shelf registration | Nov 24, 2025 | — |
| 8-K |
Current report
Agreement ended
|
Nov 18, 2025 | Nov 17, 2025 |
| 10-Q | Quarterly report | Nov 14, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 14, 2025 | Nov 14, 2025 |
| 8-K |
Current report
Other events
|
Nov 7, 2025 | Nov 7, 2025 |
| 424B5 | Prospectus supplement | Nov 7, 2025 | — |
| 8-K |
Current report
Other events
|
Sep 17, 2025 | Sep 17, 2025 |
| 8-K |
Current report
Other events
|
Sep 10, 2025 | Sep 10, 2025 |
| 8-K |
Current report
Other events
|
Aug 25, 2025 | Aug 22, 2025 |
| SCHEDULE 13G | Ownership over 5% (passive) | Aug 14, 2025 | — |
| 10-Q | Quarterly report | Aug 13, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 13, 2025 | Aug 13, 2025 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Jul 30, 2025 | Jul 30, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jul 16, 2025 | Jul 15, 2025 |
| 8-K |
Current report
Listing notice
|
Jul 7, 2025 | Jul 2, 2025 |
| 8-K |
Current report
Auditor change
|
Jun 5, 2025 | Jun 3, 2025 |
| ARS | Annual report to shareholders | Jun 2, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Jun 2, 2025 | — |
| DEF 14A | Proxy statement | Jun 2, 2025 | Jun 2, 2025 |
| PRE 14A | Preliminary proxy statement | May 23, 2025 | May 23, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
May 21, 2025 | May 20, 2025 |
| 8-K |
Current report
Listing notice
|
May 16, 2025 | May 14, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 15, 2025 | — |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 14, 2025 | May 14, 2025 |
| 10-Q | Quarterly report | May 14, 2025 | Mar 31, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 9, 2025 | — |
| EFFECT | Filing | Apr 23, 2025 | — |
| 424B3 | Prospectus | Apr 23, 2025 | — |
| CORRESP | Letter to the SEC | Apr 21, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 21, 2025 | — |
| S-3 | Shelf registration | Apr 15, 2025 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Apr 15, 2025 | Apr 15, 2025 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Apr 7, 2025 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Apr 3, 2025 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Change to shareholder rights
|
Mar 28, 2025 | Mar 27, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Mar 27, 2025 | Mar 27, 2025 |
| 8-K |
Current report
Listing notice
|
Mar 25, 2025 | Mar 25, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Mar 17, 2025 | Mar 17, 2025 |
| 10-K | Annual report | Mar 17, 2025 | Dec 31, 2024 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 14, 2025 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Feb 13, 2025 | — |
| EFFECT | Filing | Feb 5, 2025 | — |
| 424B3 | Prospectus | Feb 5, 2025 | — |
| D/A | Filing | Feb 4, 2025 | — |
| CORRESP | Letter to the SEC | Feb 3, 2025 | — |
| UPLOAD | Letter from the SEC | Feb 3, 2025 | — |
| S-3 | Shelf registration | Jan 30, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Jan 28, 2025 | — |
| D | Filing | Jan 28, 2025 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Jan 23, 2025 | — |
| 4 | Insider transaction | Jan 23, 2025 | Jan 21, 2025 |
| 4 | Insider transaction | Jan 23, 2025 | Jan 21, 2025 |
| 4 | Insider transaction | Jan 23, 2025 | Jan 21, 2025 |
| 4 | Insider transaction | Jan 23, 2025 | Jan 21, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Jan 23, 2025 | Jan 21, 2025 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Jan 21, 2025 | Jan 17, 2025 |
| 4 | Insider transaction | Jan 14, 2025 | Jan 13, 2025 |
| 4 | Insider transaction | Jan 14, 2025 | Jan 13, 2025 |
| 4 | Insider transaction | Jan 14, 2025 | Jan 13, 2025 |
| 4 | Insider transaction | Jan 14, 2025 | Jan 13, 2025 |
| 4 | Insider transaction | Jan 14, 2025 | Jan 13, 2025 |
| 4 | Insider transaction | Jan 14, 2025 | Jan 13, 2025 |
| 4 | Insider transaction | Jan 14, 2025 | Jan 13, 2025 |
| 4 | Insider transaction | Jan 14, 2025 | Jan 13, 2025 |
| 4 | Insider transaction | Jan 14, 2025 | Jan 13, 2025 |
| 4 | Insider transaction | Jan 14, 2025 | Jan 13, 2025 |
| 4 | Insider transaction | Jan 14, 2025 | Jan 13, 2025 |
| SC 13G/A | Amended ownership over 5% (passive) | Nov 14, 2024 | — |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 14, 2024 | Nov 13, 2024 |
| 10-Q | Quarterly report | Nov 13, 2024 | Sep 30, 2024 |
| D | Filing | Sep 27, 2024 | — |
| EFFECT | Filing | Sep 24, 2024 | — |
| 424B3 | Prospectus | Sep 24, 2024 | — |
| UPLOAD | Letter from the SEC | Sep 23, 2024 | — |
| CORRESP | Letter to the SEC | Sep 23, 2024 | — |
| S-3 | Shelf registration | Sep 19, 2024 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Sep 17, 2024 | Sep 16, 2024 |
| S-8 | Employee stock plan registration | Aug 7, 2024 | — |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 7, 2024 | Aug 7, 2024 |
| 10-Q | Quarterly report | Aug 7, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Other events
|
Aug 2, 2024 | Aug 2, 2024 |
| 424B5 | Prospectus supplement | Aug 2, 2024 | — |
| 424B3 | Prospectus | Jul 15, 2024 | — |
| EFFECT | Filing | Jul 12, 2024 | — |
| CORRESP | Letter to the SEC | Jul 10, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 8, 2024 | — |
| S-3 | Shelf registration | Jul 3, 2024 | — |
| 8-K |
Current report
Material agreement
|
Jun 7, 2024 | Jun 7, 2024 |
| 424B5 | Prospectus supplement | Jun 7, 2024 | — |
| 8-K |
Current report
Other events
|
Jun 5, 2024 | Jun 4, 2024 |
| 8-K |
Current report
Listing notice
|
May 24, 2024 | May 20, 2024 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Change to shareholder rights
|
May 17, 2024 | May 17, 2024 |
| 10-Q | Quarterly report | May 15, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 15, 2024 | May 15, 2024 |
| 8-K |
Current report
Listing notice, Other events
|
May 15, 2024 | May 14, 2024 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
May 14, 2024 | May 14, 2024 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
May 7, 2024 | May 7, 2024 |
| ARS | Annual report to shareholders | Mar 26, 2024 | Dec 31, 2023 |
| DEFA14A | Additional proxy material | Mar 26, 2024 | — |
| DEF 14A | Proxy statement | Mar 26, 2024 | Mar 5, 2024 |
| 10-K | Annual report | Mar 21, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Mar 21, 2024 | Mar 21, 2024 |
| PRE 14A | Preliminary proxy statement | Mar 4, 2024 | Feb 28, 2024 |
| SC 13G | Ownership over 5% (passive) | Feb 14, 2024 | — |
| 8-K |
Current report
Shareholder vote results
|
Jan 12, 2024 | Jan 12, 2024 |
| 4 | Insider transaction | Jan 5, 2024 | Jan 4, 2024 |
| 4 | Insider transaction | Jan 5, 2024 | Jan 4, 2024 |
| 4 | Insider transaction | Jan 5, 2024 | Jan 4, 2024 |
| 4 | Insider transaction | Jan 5, 2024 | Jan 4, 2024 |
| 4 | Insider transaction | Jan 5, 2024 | Jan 4, 2024 |
| 4 | Insider transaction | Jan 5, 2024 | Jan 4, 2024 |
| 4 | Insider transaction | Jan 5, 2024 | Jan 4, 2024 |
| 4 | Insider transaction | Jan 5, 2024 | Jan 4, 2024 |
| 4 | Insider transaction | Jan 5, 2024 | Jan 4, 2024 |
| 4 | Insider transaction | Jan 5, 2024 | Jan 4, 2024 |
| 4 | Insider transaction | Jan 5, 2024 | Jan 4, 2024 |
| EFFECT | Filing | Dec 15, 2023 | — |
| 424B3 | Prospectus | Dec 15, 2023 | — |
| CORRESP | Letter to the SEC | Dec 13, 2023 | — |
| UPLOAD | Letter from the SEC | Dec 13, 2023 | — |
| DEF 14A | Proxy statement | Dec 8, 2023 | Dec 7, 2023 |
| S-3 | Shelf registration | Dec 7, 2023 | — |
| PRE 14A | Preliminary proxy statement | Nov 29, 2023 | Nov 28, 2023 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Change to shareholder rights
|
Nov 17, 2023 | Nov 16, 2023 |
| 8-K |
Current report
Listing notice
|
Nov 16, 2023 | Nov 15, 2023 |
| 10-Q | Quarterly report | Nov 9, 2023 | Sep 30, 2023 |
| 8-K |
Current report
Results of operations, Auditor change, Regulation FD disclosure
|
Nov 9, 2023 | Nov 9, 2023 |
| S-8 | Employee stock plan registration | Sep 14, 2023 | — |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 10, 2023 | Aug 10, 2023 |
| 10-Q | Quarterly report | Aug 10, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Auditor change, Officer or director change, Shareholder vote results
|
Aug 3, 2023 | Jul 28, 2023 |
| EFFECT | Filing | Jul 27, 2023 | — |
| 424B4 | Prospectus | Jul 27, 2023 | — |
| CORRESP | Letter to the SEC | Jul 25, 2023 | — |
| UPLOAD | Letter from the SEC | Jul 14, 2023 | — |
| DEFA14A | Additional proxy material | Jul 12, 2023 | — |
| S-1 | Registration statement | Jul 7, 2023 | — |
Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- DRMA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1853816
- Former names
- Dermata Therapeutics, Inc. (until Nov 2, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.